Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

Hims & Hers Health, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 25, 2025 to Discuss Your Rights ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there.10 stocks we ...

NEW ORLEANS, July 16, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working with Novo Nordisk in the future despite the termination of its earlier ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy collaboration turned on the telehealth provider’s selling of a copycat weight-loss ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.